StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Keytruda (pembrolizumab by Quarter

Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Keytruda (pembrolizumab: $7,904M in Q2 2026, down 0.7% from a year earlier.

Latest, Q2 2026
7,904
Period ended Jun 30, 2026
Change on a year earlier
-0.7%
7,956 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Keytruda | 7,904 | 7,956 | -1 | 4,611 | 4,749 | -3 | 3,293 | 3,207 | 3”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKeytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20267,904-0.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20267,906+9.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20258,337+6.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 20258,142+9.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 20257,956+9.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20257,205+3.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 20247,836+18.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 20247,429+17.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 20247,270+15.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 20246,947+19.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 20236,608+21.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20236,338+16.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 20236,271+19.4%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 20235,795+20.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 20225,450+19.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 20225,426+19.7%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up keytruda (pembrolizumab

Cite this data

StockData. (2026). Merck Keytruda (pembrolizumab ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-keytruda

See every metric in the Merck KPI table. Data updated Oct 26, 2026.